The comparison between EUPHAS 2 and epidemiologic studies in France [ 26 ] and Asia [ 27 ] showed a trend to clinical improvement without significant adverse event associated with endotoxin removal.
← all excerpts
Polymyxin-B hemoperfusion in septic patients: analysis of a multicenter registry.
1
—
—